Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Sortiert nach
Open Access
    Datensatz exportieren als...
  • BibTeX
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
PloS one, 2014-07, Vol.9 (7), p.e101819-e101819
2014
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA‐SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐5 STUDY
HemaSphere, 2022-06, Vol.6 (Suppl), p.829-830
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Is multiple myeloma a chronic disease?
HAEMATOLOGICA, 2012, Vol.97, p.345
2012
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Bortezomib, response and retreatment in 1st, 2nd, 3rd and 4th line of treatment in patients with multiple myeloma
HAEMATOLOGICA, 2012, Vol.97, p.610
2012
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Follow up of multiple myeloma patients with renal impairment during a 10 year period
HAEMATOLOGICA, 2012, Vol.97, p.599
2012
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery
Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2191-2199
2012
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
BLOOD, 2022-11, Vol.140 (Supplement 1), p.12605-12606
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1
JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16_suppl), p.8033-8033
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
European journal of haematology, 2019-12, Vol.103 (6), p.588-596
2019
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
European journal of haematology, 2022-12, Vol.109 (6), p.749-754
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Response to Caravita di Toritto and Rago
European journal of haematology, 2023-02, Vol.110 (2), p.224-225
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population‐based data from the Swedish Myeloma Register
European journal of haematology, 2017-09, Vol.99 (3), p.216-222
2017
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy
American journal of hematology, 2021-11, Vol.96 (11), p.E443-E446
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
American journal of hematology, 2021-08, Vol.96 (8), p.925-933
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study
JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.8019-8019
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
BLOOD, 2021-11, Vol.138 (Supplement 1), p.897-897
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden
Cancer medicine (Malden, MA), 2024-04, Vol.13 (8), p.e7048-n/a
2024
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma
Cancer medicine (Malden, MA), 2023-11, Vol.12 (22), p.20736-20744
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
European journal of haematology, 2021-04, Vol.106 (4), p.546-554
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
European journal of haematology, 2019-09, Vol.103 (3), p.247-254
2019
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
PloS one, 2015-09, Vol.10 (9), p.e0138248-e0138248
2015
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
British journal of haematology, 2014-03, Vol.164 (5), p.684-693
2014
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Cancers, 2024-02, Vol.16 (5), p.1024
2024
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients
BLOOD, 2012-11, Vol.120 (21), p.5033-5033
2012
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
European journal of haematology, 2014-01, Vol.92 (1), p.19-25
2014
Volltextzugriff (PDF)
1 – 25 von 33
Suche als RSS-Feed
Suchergebnisse filtern
Filter anzeigen